Kennedy Capital Management’s Exagen XGN Stock Holding History

Kennedy Capital Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Buy	493,660 +13,631	+3%	+$52.7K	0.03%	444
2025 Q4	$2.92M	Sell	480,029 -71,819	-13%	-$654K	0.06%	385
2025 Q3	$6.06M	Buy	551,848 +241,127	+78%	+$2.14M	0.13%	257
2025 Q2	$2.17M	Buy	310,721 +15,568	+5%	+$94.6K	0.05%	433
2025 Q1	$1.06M	Buy	295,153 +110,680	+60%	+$418K	0.03%	508
2024 Q4	$756K	Buy	184,473 +14,920	+9%	+$53.8K	0.02%	616
2024 Q3	$524K	Buy	169,553 +93,040	+122%	+$241K	0.01%	634
2024 Q2	$139K	Buy	+76,513	New	+$130K	﹤0.01%	689

Other funds holding XGN

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Kennedy Capital Management's XGN Position: Q1 2026 in Review

Kennedy Capital Management increased its Exagen (XGN) stake by 2.8% in Q1 2026, buying an estimated $52.7K and bringing the position to 493,660 shares worth $1.48M. The position accounts for 0.03% of the portfolio, ranked #444.

Kennedy Capital Management first reported a position in XGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.06M in Q3 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

Kennedy Capital Management held 493,660 shares of Exagen worth $1.48M as of Q1 2026.
Kennedy Capital Management bought 13,631 Exagen shares in Q1 2026, an estimated $52.7K.
Exagen made up 0.03% of Kennedy Capital Management's portfolio in Q1 2026, its #444 holding.
Kennedy Capital Management first reported a position in Exagen in Q2 2024 and has held it in 8 quarters since.
Kennedy Capital Management's Exagen position peaked at $6.06M in Q3 2025.
61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.